IPO Notes: Suja Life (SUJA) is a Bet on...Soda?

Why the decline in the recent IPO improves the R/R, but still leaves potential issues for investors looking to get involved

COTW: Restaurants Losing Their Glitz And Glam

Visualizing the decline in valuations in various restaurant concepts while highlighting which the market still seems to give hope to

The 'FOMO' Is Unbearably Real

Why a recent post from a fellow portfolio manager got us thinking about the current FOMO environment, and why staying the course "generally" works out in the long term

The Sift No.1

Analytical Perspectives on Equity Selection and Market Data.

NKTR: "Winning By Being Second"

Why Nektar Therapeutics atopic dermatitis (AtD) drug could be significantly undervalued despite being a potential second-line drug treatment option

CGCM Q1'26 Quarterly Letter

Part 2: Q4 Earnings Update On High Conviction Investment - EVLV

Quick update on EVLV and why we think that FY'26 guide hints at a long-term opportunity for price appreciation above $10/share.

Part 1: Q4 Earnings Updates and Capturing Cheap Growth? [REAL, KITS, WW]

Going over Q4'25 earnings for current investors and why they might standout for new investors looking new areas for capital deployment

LNSR Terminates Deal - Is It Worth More Than the $14/Share?

A quick walkthrough on the math post-deal break, and could LNSR still be compelling as a standalone company?

Understanding "Risk" From One of the Greats — Howard Marks

What one of the best investors on Wall Street has to say about "risk" and what we can learn from it